Entering text into the input field will update the search result below

Eleven Biotherapeutics' (EBIO) CEO Abbie Celniker on Q2 2014 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts
145.52K Followers

Eleven Biotherapeutics, Inc. (EBIO) Q2 2014 Earnings Conference Call August 13, 2014 8:30 AM ET

Executives

Abbie C. Celniker - President and CEO
Gregory D. Perry - Chief Business Officer and CFO
Michael H. Goldstein - Medical Research
Leah Monteiro - Corporate Communications Manager

Analysts

Liav Abraham - Citigroup
Jason Gerberry - Leerink Partners
Tyler Van Buren - Cowen & Company

Operator

Welcome to Eleven Biotherapeutics Second Quarter 2014 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors & Media section of Eleven’s website at ir.elevenbio.com. This call is the property of Eleven Biotherapeutics and recordings, reproduction and transmission of the call without the express written consent of Eleven Biotherapeutics is strictly prohibited. As a reminder, today’s call is being recorded.

I would now like to introduce Leah Monteiro, Corporate Communications Manager of Eleven Biotherapeutics. You may begin.

Leah Monteiro

Thank you. Good morning. The press release with the company’s second quarter 2014 financial results became available at 7:30 AM Eastern Time today. It can be found on the Investors & Media section of the company’s website at ir.elevenbio.com.

Before we begin, I will read Eleven Biotherapeutics Safe Harbor notice regarding forward-looking statements. During today’s call, we may make forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. It may include statements about our future expectations, plans and prospects, clinical development and regulatory timelines of potential success with our product candidates, financial projections, projections for 2014, 2015 and 2016 milestones and upcoming events and presentations.

Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the Risk Factors section in our quarterly report on Form 10-Q for the period ended

Recommended For You

About CARM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

More on CARM